Ironwood Pharmaceuticals Inc (IRWD) stock
IRWDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/3062% below fair value
$4.85+0.02 (+0.41%)
Close on Nov 16, 2026Market cap $801.41MP/E 6.3Yield –
Ironwood Pharmaceuticals r&d expenses
Research and development expenses are spending on new products and technology.
Ironwood Pharmaceuticals's R&D Expenses for the twelve months ending Jun 30, 2026 was $88.69M, down 16.3% year over year. For fiscal 2025 it was $95.14M, down 14.6% from the year before. Over ten years it grew -1.3% a year on average. The highest annual figure on record is $139.49M in fiscal 2016.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $95.14M | -14.6% |
| FY2024 | Dec 31, 2024 | $111.42M | -4.0% |
| FY2023 | Dec 31, 2023 | $116.09M | +162.3% |
| FY2022 | Dec 31, 2022 | $44.27M | -37.1% |
| FY2021 | Dec 31, 2021 | $70.41M | -20.1% |
| FY2020 | Dec 31, 2020 | $88.06M | -23.5% |
| FY2019 | Dec 31, 2019 | $115.04M | +13.8% |
| FY2018 | Dec 31, 2018 | $101.06M | +14.7% |
| FY2017 | Dec 31, 2017 | $88.15M | -36.8% |
| FY2016 | Dec 31, 2016 | $139.49M | +28.3% |
| FY2015 | Dec 31, 2015 | $108.75M | +6.7% |
| FY2014 | Dec 31, 2014 | $101.89M | -0.5% |
| FY2013 | Dec 31, 2013 | $102.38M | -9.8% |
| FY2012 | Dec 31, 2012 | $113.47M | +31.8% |
| FY2011 | Dec 31, 2011 | $86.09M | +11.2% |
| FY2010 | Dec 31, 2010 | $77.45M | +1.8% |
| FY2009 | Dec 31, 2009 | $76.10M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $22.42M | -4.1% |
| Q1 FY2026 | Mar 31, 2026 | $21.94M | -20.0% |
| Q4 FY2025 | Dec 31, 2025 | $21.86M | -13.9% |
| Q3 FY2025 | Sep 30, 2025 | $22.47M | -24.7% |
| Q2 FY2025 | Jun 30, 2025 | $23.37M | -23.1% |
| Q1 FY2025 | Mar 31, 2025 | $27.43M | +6.3% |
| Q4 FY2024 | Dec 31, 2024 | $25.39M | -28.8% |
| Q3 FY2024 | Sep 30, 2024 | $29.83M | -9.6% |
| Q2 FY2024 | Jun 30, 2024 | $30.39M | -12.1% |
| Q1 FY2024 | Mar 31, 2024 | $25.82M | +100.9% |
| Q4 FY2023 | Dec 31, 2023 | $35.68M | +241.5% |
| Q3 FY2023 | Sep 30, 2023 | $32.99M | +185.7% |
| Q2 FY2023 | Jun 30, 2023 | $34.58M | +201.9% |
| Q1 FY2023 | Mar 31, 2023 | $12.85M | +18.7% |
| Q4 FY2022 | Dec 31, 2022 | $10.45M | -67.2% |
| Q3 FY2022 | Sep 30, 2022 | $11.55M | +5.8% |
| Q2 FY2022 | Jun 30, 2022 | $11.45M | -5.8% |
| Q1 FY2022 | Mar 31, 2022 | $10.82M | -30.1% |
| Q4 FY2021 | Dec 31, 2021 | $31.85M | +95.8% |
| Q3 FY2021 | Sep 30, 2021 | $10.91M | -49.7% |
| Q2 FY2021 | Jun 30, 2021 | $12.16M | -44.9% |
| Q1 FY2021 | Mar 31, 2021 | $15.48M | -44.8% |
| Q4 FY2020 | Dec 31, 2020 | $16.27M | -38.7% |
| Q3 FY2020 | Sep 30, 2020 | $21.69M | -21.3% |
| Q2 FY2020 | Jun 30, 2020 | $22.08M | -23.2% |
| Q1 FY2020 | Mar 31, 2020 | $28.03M | -13.0% |
| Q4 FY2019 | Dec 31, 2019 | $26.54M | -6.0% |
| Q3 FY2019 | Sep 30, 2019 | $27.55M | -5.5% |
| Q2 FY2019 | Jun 30, 2019 | $28.76M | +24.0% |
| Q1 FY2019 | Mar 31, 2019 | $32.20M | -11.8% |
| Q4 FY2018 | Dec 31, 2018 | $28.24M | -29.6% |
| Q3 FY2018 | Sep 30, 2018 | $29.16M | -21.3% |
| Q2 FY2018 | Jun 30, 2018 | $23.19M | -37.9% |
| Q1 FY2018 | Mar 31, 2018 | $36.51M | +8.3% |
| Q4 FY2017 | Dec 31, 2017 | $40.12M | +4.4% |
| Q3 FY2017 | Sep 30, 2017 | $37.07M | -1.2% |
| Q2 FY2017 | Jun 30, 2017 | $37.34M | – |
| Q1 FY2017 | Mar 31, 2017 | $33.70M | – |
| Q4 FY2016 | Dec 31, 2016 | $38.44M | – |
| Q3 FY2016 | Sep 30, 2016 | $37.53M | – |
See a number that looks wrong?